Ignite Creation Date:
2024-05-06 @ 2:46 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04423926
Status:
RECRUITING
Last Update Posted:
2020-06-16
First Post:
2020-06-08
Brief Title:
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
A Phase II Prospective Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL
Status:
RECRUITING
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The prognosis of PTCL except early stage ALK ALCL is dismal Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory PTCL The investigators therefore design this phase II study to investigate the safety and efficacy of lenalidomide in combination with CHOP in patients with treatment-naive PTCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None